Evotec SE
EVOHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeEvotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. Valued at $661.0M, EVO is a small-cap name in its sector. It operates in two segments, Shared R&D and Just Evotec Biologics.
Market Cap
$661.0M
Beta
1.26
P/E (TTM)
—
P/E (Fwd)
-9.79
EPS (TTM)
$-0.64
EPS (Fwd)
$-0.19
ROE
-26.1%
ROA
-5.4%
Cash
$465.6M
Total Debt
$475.9M
Free CF
-$81.0M
52W Change
-46.7%
Annual Financials
Cash vs Debt
Where EVO stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, EVO finished 33.82% below its 150-day moving average ($2.72) and 36.84% below its 200-day moving average ($2.85). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is EVO overbought or oversold?
At the September 2, 2026 close, EVO's RSI(14) was 21.7, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $465.6M in cash, though total debt stands at $475.9M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$81.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -26.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been relatively flat, moving from $751.4M (2022) to $788.4M (2025).
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing EVO.